Erythropoietin induces miRNA-210 by JAK2/STAT5 signaling in PBMCs of End-stage Renal Disease patients.

Publisher: Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies Country of Publication: England NLM ID: 101229646 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1742-4658 (Electronic) Linking ISSN: 1742464X NLM ISO Abbreviation: FEBS J Subsets: MEDLINE

Original Publication: Oxford, UK : Published by Blackwell Pub. on behalf of the Federation of European Biochemical Societies, c2005-

Anemia/*drug therapy ; Erythropoietin/*pharmacology ; Janus Kinase 2/*metabolism ; Kidney Failure, Chronic/*therapy ; Leukocytes, Mononuclear/*drug effects ; MicroRNAs/*genetics ; Renal Dialysis/*adverse effects ; STAT5 Transcription Factor/*metabolism; Aged ; Anemia/etiology ; Anemia/metabolism ; Anemia/pathology ; Female ; Humans ; Janus Kinase 2/genetics ; Kidney Failure, Chronic/pathology ; Leukocytes, Mononuclear/metabolism ; Male ; MicroRNAs/blood ; Recombinant Proteins/pharmacology ; STAT5 Transcription Factor/genetics

Anemia of chronic kidney disease is associated with blunted response/resistance to erythropoietin-stimulating agents (ESAs) in hemodialysis (HD) patients. Several molecules have been successfully associated with ESA responsiveness; however, none of them is now considered a valid therapeutic biomarker of erythropoietin resistance in these patients. We performed an evaluation of the level of specific plasma circulating miRNAs in blood samples of HD patients, in relation to ESA treatment, with a follow-up of 1 year (T0-T3). We found significantly lower circulating levels of all miRNAs analyzed at baseline (T0) in HD patients vs. healthy control (HC). The plasmatic levels of miRNA-210 resulted significantly and negatively associated with Erythropoietin Resistance Index (ERI), and the variance of ΔmiRNA-210 (miRNA-210 T3 minus miRNA-210 T0 ) explained significant percentage of ΔERI (ERI T3 minus ERI T0 ) variance. The receiver operating characteristic analysis at T0 showed that the plasmatic level of miRNA-210 could distinguish HD patients with positive or negative trend in ERI at T3. In vitro, recombinant human erythropoietin (EPO) induced significant release of miRNA-210 from cultured peripheral blood mononuclear cells, through the activation of Janus kinase 2 (JAK2)/ signal transducer and activator of transcription 5 (STAT5) signaling, but not by the activation of the MAPK protein 38α and extracellular signal-regulated kinase ½. Accordingly, HD patients with negative ΔERI showed higher level of phosphor-Janus kinase 2 and nuclear translocation of phosphor-signal transducer and activator of transcription 5. vs. patients with positive ΔERI or HC. Our data highlighted that chronic HD significantly reduces the circulating level of the miRNAs evaluated; within the targets analyzed, the miRNA-210 could be considered as a prognostic indicator of ESA responsiveness and index for anemia management.
(© 2020 Federation of European Biochemical Societies.)

World Health Organization (1968) Nutritional anaemias: report of a WHO scientific group. World Health Organ Tech Rep Ser 405, 5-37.
Nurko S (2006) Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleve Clin J Med 73, 289-297.
Berns JS (2005) Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Semin Dial 18, 22-29.
Shih CJ, Chen YT, Ou SM, Yang WC, Kuo SC & Tarng DC (2014) The impact of dialysis therapy on older patients with advanced chronic kidney disease: a nationwide population-based study. BMC Med 12, 169.
De Nicola L, Minutolo R & Gallo C (2005) Management of hypertension in chronic kidney disease: the Italian multicentric study. J Nephrol 18, 397-404.
Portolés J, López-Gómez JM, Aljama P &MAR Study Group (2007) A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. Nephrol Dial Transplant 22, 500-507.
Priyadarshi A & Shapiro JI (2006) Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 19, 273-278.
Provenzano M, Coppolino G, De Nicola L, Serra R, Garofalo C, Andreucci M & Bolignano D (2019) Unraveling cardiovascular risk in renal patients: a new take on old tale. Front Cell Dev Biol 3, 314.
Eknoyan G, Latos DL & Lindberg J (2003) Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 41, 868-876.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361, 2019-2032.
Koulouridis I, Alfayez M, Trikalinos TA, Balk EM & Jaber BL (2013) Dose of erythropoiesis - stimulating agents and adverse outcomes in CKD: a meta-regression analysis. Am J Kidney Dis 61, 44-56.
Drueke T (2001) Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16, 25-28.
Bonomini M, Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Consoli A, Amoroso L, Gizzi F, De Lutiis MA & Felaco M (2005) Adherence of uremic erythrocytes to vascular endothelium decreases endothelial nitric oxide synthase expression. Kidney Int 67, 1899-1906.
Smrzova J, Balla J & Bárány P (2005) Inflammation and resistance to erythropoiesis -stimulating agents- what do we know and what needs to be clarified? Nephrol Dial Transplant 20, 2-7.
Ha M & Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15, 509-524.
Otto T, Candido SV, Pilarz MS, Sicinska E, Bronson RT, Bowden M, Lachowicz IA, Mulry K, Fassl A, Han RC et al. (2017) Cell cycle-targeting microRNAs promote differentiation by enforcing cell-cycle exit. Proc Natl Acad Sci USA 114, 10660-10665.
Winter J, Jung S, Keller S, Gregory RI & Diederichs S (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11, 228-234.
Cortez M & Calin G (2009) MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 9, 703-711.
Weber JA, Baxter DH & Zhang S (2013) The microRNA spectrum in 12 body fluids. Clin Chem 56, 1733-1741.
Kim YJ, Maizel A & Chen X (2014) Traffic into silence: endomembranes and post-transcriptional RNA silencing. EMBO J 33, 968-980.
Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y & Ochiya T (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285, 17442-17452.
Bianchi F, Nicassio F, Marzi M, Belloni E, Dall'Olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G & Di Fiore PP (2011) A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3, 495-503.
Dimmeler S & Nicotera P (2013) MicroRNAs in age-related diseases. EMBO Mol Med 5, 180-190.
Chen Z, Zhan Y, Chi J, Guo S, Zhong X, He A, Zheng J, Gong Y, Li X& Zhou L (2018) Using microRNAs as novel predictors of urologic cancer survival: an integrated analysis. EBioMedicine 34, 94-107.
Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS & Mirkin CA (2016) Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci USA 113, 10655-10660.
Hulsmans M, De Keyzer D & Holvoet P (2011) MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J 25, 2515-2527.
Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY & Gleadle JM (2011) Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 26, 3794-3802.
Chen NX, Kiattisunthorn K, O'Neill KD, Chen X, Moorthi RN, Gattone VH, Allen MR & Moe SM (2013) Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS ONE 8, e64558.
Kroh EM, Parkin RK, Mitchell PS & Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50, 298-301.
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD & Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13, 423-433.
Kosaka N, Sugiura K, Yamamoto Y, Yoshioka Y, Miyazaki H, Komatsu N, Ochiya T & Kato T (2008) Identification of erythropoietin-induced microRNAs in haematopoietic cells during erythroid differentiation. Br J Haematol 142, 293-300.
Pesce M, Felaco P, Franceschelli S, Speranza L, Grilli A, Anna De Lutiis M, Ferrone A, Sirolli V, Bonomini M, Felaco M et al. (2014) Effect of erythropoietin on primed leucocyte expression profile. Open Biol 4, 140026.
Bergelson S, Klingmüller U, Socolovsky M, Hsiao JG & Lodish HF (1998) Tyrosine residues within the intracellular domain of the erythropoietin receptor mediate activation of AP-1 transcription factors. J Biol Chem 273, 2396-2401.
Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ & CGTP Collaborators (2013) The concise guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170, 1797-1867.
Penta K & Sawyer ST (1995) Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem 270, 31282-31287.
Lv LL, Cao YH, Ni HF, Xu M, Liu D, Liu H, Chen PS & Liu BC (2006) MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. Am J Physiol Renal Physiol 305, F1220-F1227.
Oberbauer R, Schreiner GF & Meyer TW (1995) Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 48, 1226-1232.
Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM & Klotman PE (1995) Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int 47, 1462-1469.
van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG & Masereeuw R (2006) Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34, 1393-1397.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108, 5003-5008.
Quévillon Huberdeau M, Zeitler DM, Hauptmann J, Bruckmann A, Fressigné L, Danner J, Piquet S, Strieder N, Engelmann JC, Jannot G et al. (2017) Phosphorylation of Argonaute proteins affects mRNA binding and is essential for microRNA-guided gene silencing in vivo. EMBO J 36, 2088-2106.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105, 10513-10518.
Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN et al. (2014) Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA 111, 14888-14893.
Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J, Risgaard B, Tomsits P, Hildebrand B, Kääb S, Wakili R et al. (2017) Stability of circulating blood-based MicroRNAs - pre-analytic methodological considerations. PLoS ONE 12, e0167969.
Komatsu N, Yamamoto M, Fujita H, Miwa A, Hatake K, Endo T, Okano H, Katsube T, Fukumaki Y & Sassa S (1993) Establishment and characterization of an erythropoietin dependent subline, UT-7/EPO, derived from human leukemia cell line, UT-7. Blood 82, 456-464.
Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC & Martelli F (2008) MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 283, 15878-15883.
Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, Hassan K, Shkolnik G, Geron R & Kristal B (2005) Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 16, 2431-2438.
Pavese I, Satta F, Todi F, Di Palma M, Piergrossi P, Migliore A, Piselli P, Borghesi R, Mancino G, Brunetti E et al. (2010) High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients. Ann Oncol 21, 1523-1528.
Martino F, Lorenzen J, Schmidt J, Schmidt M, Broll M, Görzig Y, Kielstein JT & Thum T (2012) Circulating microRNAs are not eliminated by hemodialysis. PLoS ONE 7, e38269.
Caswell M, Pike LA, Bull BS & Stuart J (1993) Effect of patient age on tests of the acute-phase response. Arch Pathol Lab Med 117, 906-909.
Sox H & Liang M (1986) The erythrocyte sedimentation rate. Ann Intern Med 104, 515-523.
Biasucci LM (2004) CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice. Clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 110, 560-567.
Gabay C & Kashner I (1999) Acute phase proteins and other systemic responses to inflammation. N Engl J Med 340, 448-454.
Pesce M, Ferrone A, Rizzuto A, Tatangelo R, Iezzi I, Ladu S, Franceschelli S, Speranza L, Patruno A, Felaco M et al. (2014) SHP-1 expression is associated with cytokines and psychopathological status in unmedicated first episode schizophrenia patients. Brain Behav Immun 41, 251-260.
Pesce M, Speranza L, Franceschelli S, Ialenti V, Iezzi I, Patruno A, Rizzuto A, Robazza C, De Lutiis MA, Felaco M et al. (2013) Positive correlation between serum interleukin-1β and state anger in rugby athletes. Aggress Behav 39, 141-148.
Kristal B, Shurtz-Swirski R & Tanhilevski O, Shapiro G, Shkolnik G, Chezar J, Snitkovsky T, Cohen-Mazor M & Sela S (2008) Epoetin-alpha: preserving kidney function via attenuation of polymorphonuclear leukocyte priming. Isr Med Assoc J 10, 266-272.
Schwartz C, Willebrand R, Huber S, Rupec RA, Wu D, Locksley R & Voehringer D (2015) Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB-induced Bcl-xL for inhibition of apoptosis. Blood 125, 3896-3904.
Kirkeby A, van Beek J, Nielsen J, Leist M & Helboe L (2007) Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods 164, 50-58.
Felaco M, Di Maio FD, De Fazio P, D'Arcangelo C, De Lutiis Ma, Varvara G, Grilli A, Barbacane Rc, Reale M & Conti P (2000) Localization of the e-NOS enzyme in endothelial cells and odontoblasts of healthy human dental pulp. Life Sci 68, 297-306.
Speranza L, Pesce M, Franceschelli S, Bucciarelli T, Gallina S, Riccioni G, Patruno A & Felaco M (2013) The biological evaluation of ADMA/SDMA and eNOS in patients with ACHF. Front Biosci 5, 551-557.
Youden WJ (1950) Index for rating diagnostic tests. Cancer 3, 32-35.

Keywords: JAK2; PBMCs; STAT5; anemia; erythropoietin; miRNA-210

0 (MIRN210 microRNA, human)
0 (MicroRNAs)
0 (Recombinant Proteins)
0 (STAT5 Transcription Factor)
11096-26-7 (Erythropoietin)
EC 2.7.10.2 (JAK2 protein, human)
EC 2.7.10.2 (Janus Kinase 2)

Date Created: 20200321 Date Completed: 20210524 Latest Revision: 20210524

20250114

10.1111/febs.15302

32196922